Citi downgraded Pactiv Evergreen (PTVE) to Neutral from Buy with a price target of $18, up from $13. The firm sees limited upside to the shares following the announced combination with Novolex. Pactiv shares traded up 18% to close at $17.36 Monday, implying a reasonably tight spread on the deal, the analyst tells investors in a research note.
Education
About Us
Working with TipRanks
Follow Us
1